Equities

BioMaxima SA

BioMaxima SA

Actions
Health CareMedical Equipment and Services
  • Price (PLN)14.30
  • Today's Change-0.70 / -4.67%
  • Shares traded4.20k
  • 1 Year change-46.94%
  • Beta--
Data delayed at least 15 minutes, as of May 02 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BioMaxima SA is a Poland-based company active in the laboratory diagnostics sector. It manufactures and distributes reagents and equipment for the laboratory diagnosis. It produces reagents for the in vitro diagnosis. The main product groups offered by BioMaxima include: diagnostic reagents and analyzers for clinical biochemistry; rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers and drugs of abuse; urine analysis systems; hematology analyzers and reagents; ion-selective analyzers and reagents; reagents and immunological analyzers of cardiac markers; glucometers; analyzers for gasometric tests and critical blood parameters tests. The Company supplies hospitals and laboratories in Poland, as well as in Lithuania, Latvia, Romania and France. On March 20, 2014, the Company merged with its wholly owned subsidiary Cebo Sp z o o.

  • Revenue in PLN (TTM)49.06m
  • Net income in PLN807.00k
  • Incorporated2008
  • Employees--
  • Location
    BioMaxima SAul. Vetterow 5LUBLIN 20-277PolandPOL
  • Phone+48 814408371
  • Fax+48 817442915
  • Websitehttps://biomaxima.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
GENOMED SA22.48m996.34k39.11m--39.253.8624.221.740.75410.754117.017.662.006.2913.81--8.877.9010.249.3342.8538.564.433.934.103,257.61----9.853.87193.38-7.69-32.19--
Inventionmed SA610.00-2.46m41.77m9.00--7.79--68,482.22-0.0121-0.01210.000.02640.00002--0.000467.78-7.00-18.09-11.73-23.28-1,288.53-48.77-403,196.70-43,186.79---2.11-----85.01--88.90------
BioMaxima SA49.06m807.00k59.96m--80.771.1819.381.220.17710.177111.3712.140.67112.035.48--1.1018.571.2827.4044.5940.021.6413.160.84987.500.152--79.4635.74182.00104.6035.44--
Medicofarma Biotech SA750.81k-2.67m60.50m----6.09--80.58-0.0393-0.03930.0110.14630.04683.571.51---16.65-13.16-21.54-15.8665.4529.92-355.88-37.810.6358-14.54-----82.34-31.48-68.11------
BIOGENED SA95.56m4.20m63.37m205.0015.07--8.200.66321.711.7138.90--------466,145.20--2.92--4.1366.4268.044.403.31--3.68----20.0218.8824.3329.899.88--
Read Gene SA10.05m-1.85m65.55m11.00--14.86--6.52-0.1954-0.19541.060.37410.66648.814.51---12.24-1.71-13.14-2.1188.5788.01-18.37-3.906.46-4.19----38.7915.77-966.00------
Onesano SA13.09m-5.21m84.99m51.00--4.94--6.49-0.0812-0.08120.20830.26110.54491.986.21272,645.80-21.70-35.13-25.97--43.3852.79-39.83-32.033.40--0.0296--5.8030.63-225.52--14.67--
Data as of May 02 2024. Currency figures normalised to BioMaxima SA's reporting currency: Polish New Zloty PLN
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.